您的当前位置:首页 > 行业数据 > 全球用于治疗CHB的临床开发中的抗HBVsiRNA候选药物(2期或以上)
图片属性
图片格式:PNG 图片大小:181KB 图片尺寸:2268*1224
同报告图片
 / 4
全球用于治疗CHB的临床开发中的抗HBVsiRNA候选药物(2期或以上)_第1页
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
全球用于治疗CHB的临床开发中的抗HBVsiRNA候选药物(2期或以上)_第2页
全球用于治疗CHB的临床开发中的抗HBVsiRNA候选药物(2期或以上)_第3页
全球用于治疗CHB的临床开发中的抗HBVsiRNA候选药物(2期或以上)_第4页
全球用于治疗CHB的临床开发中的抗HBVsiRNA候选药物(2期或以上)_第5页
所属报告: 瑞博生物~B-6938.HK-港股公司研究报告:中国小核酸创新药领军者增长潜力大-260409(32页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠